19 June 2013
Keywords: speedel, welcomes, positive, spp100, ph, ii/iii, trial
Article | 18 September 2006
Swiss biopharmaceutical company Speedel said that data from Phase II/III trials of the oral renin inhibitor SPP100 (aliskiren, Rasilez) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
25 September 2006
11 September 2006
© 2013 thepharmaletter.com